Kornimate/medical-research-clean huggingface dataset:
dipeptidyl peptidase 4 inhibition facilitate healing of diabetic ulcers

Conditions: Diabetic Foot Ulcer

Summary: to investigate the effect of dipeptidyl peptidase 4 inhibition on wound healing in patients with diabetic foot ulcers, the investigators randomly divided the participants into two groups: saxagliptin with regular treatment group，placebo with regular treatment group. the clinical data are collected at the given time point. this study aimed to observe the potential protective effect of dpp4i on diabetic ulcers.

groups: diabetic ulcers, saxagliptin + regular treatment. diabetic ulcers, placebo + regular treatment. time point: initial treatment; post-treatment ( 1w ); post-treatment ( 2w ); post-treatment ( 4w ); completely healed.

Eligibility criteria:
inclusion criteria: * diagnosis of diabetes mellitus according to world health organization criteria ( treatment with insulin or an oral hypoglycemic agent, twice random glucose measurements major than 200 mg/dl, or a fasting glucose major than 140 mg/dl) * ulcer located on the legs or feet, stage iii or iv (wagner classification system) * the subject agrees to comply with study protocol requirements and all follow up visit requirements. exclusion criteria: * uncontrolled diabetes * ulcer infection * non-diabetic ulcers orthopedic or neuromuscular pathologic conditions

Keywords: diabetes wound healing dipeptidyl peptidase 4 inhibition
sort out x - combo stent versus orsiro stent

Conditions: Coronary Heart Disease; Angina Pectoris; Myocardial Infarction

Summary: the aim of the danish organisation for randomised trials with clinical outcome (sort out) is to compare the safety and efficacy of the combotm stent and orsiro™ stent in the treatment of unselected patients with ischemic heart disease, using registry detection of clinically driven events.

randomized clinical comparison of a combined sirolimus eluting and endothelial progenitor cell combo stent with a sirolimus-eluting osiro stent in patients treated with percutaneous coronary intervention.

Eligibility criteria:
inclusion criteria: * all patients aged ≥18 years who are eligible for treatment with one or several drug-eluting coronary stents at rigshospitalet or one of the three heart centers in aarhus, odense and aalborg can be included in the study. * the patients will be treated in accordance with the criteria applicable at the individual sites. * the investigators plan to include 3,140 patients. exclusion criteria: * age \< 18 years * the patient does not wish to participate * the patient is not able to consent to randomization (eg intubated patients) * the patient do not speak danish * the patient is already included in this study * the patient is already participating in other stent studies * life expectancy \<1 year * allergic to aspirin, clopidogrel, prasugrel or ticagrelor * allergic to sirolimus

Keywords: des angina pectoris stent
the effect of botulinum toxin a injections on ankle dorsiflexion following internal fixation of tibial pilon fractures

Conditions: Equinus Contracture

Summary: the purpose of this study is to determine if botulinum toxin type a (botox) injections, at the time of surgery for pilon fractures, will improve ankle range-of-motion and functionality.

to determine if the use of botulinum toxin a intramuscular injections of the gastrocsoleus complex in patients with operatively treated tibial plafond fractures will result in: 1. increased ankle dorsiflexion when compared to controls 2. increased ankle functionality as measured by the faam, and quality of life as measured by the sf-36, when compared to controls 3. a higher proportion of patients achieving at least 10 degrees of dorsiflexion when compared to controls

Eligibility criteria:
inclusion criteria: * patients 18 and older with a tibial plafond fracture to be treated by a staged protocol involving primary external fixation and definitive fixation within 3 weeks from the injury. (non-definitive, interval procedures such as repeat irrigation and debridement and fibular fixation are allowed.) exclusion criteria: * younger than 18 years of age * significant traumatic brain injury or cognitive disability that would interfere with post-operative rehabilitation and study questionnaires * nerve, vascular, or tendon injury of the lower leg: injury to the tibial or peroneal motor nerves, injury to the posterior tibial artery requiring repair, or laceration of tendons that are involved in plantar flexion or dorsiflexion of the ankle which require repair * history of prior lower extremity fracture to the tibia or ankle of the affected limb. * incarcerated patients. * patients unable or unwilling to return for follow-up examination. * pregnant or lactating patients. * history of disease affecting the neuromuscular junction (ex: myasthenia gravis). * use of aminoglycoside antibiotics at the time of definitive fixation. * ipsilateral foot injury that will impair dorsiflexion exercises: lisfranc injuries, fractures or dislocations of the talus, calcaneus, navicular, cuboid, cuneiforms, or metatarsals (phalanx fractures or dislocations will not be excluded). * patients receiving botulinum toxin a for other reasons. * patients with a known hypersensitivity to botulinum toxin a. * gustilo anderson type iii b and c. * patients with a weight greater than 115 kg - to ensure proper injection locations

Keywords: pilon tibial plafond botox ankle dorsiflexion ankle functionality ankle range of motion
digital treatments for opioids and other substance use disorders in primary care

Conditions: Drug Use Disorders; Illicit Drug Use; Alcohol-Related Disorders; Opioid Use Disorder

Summary: the digits trial addresses a critical knowledge gap: how to best implement digital treatments for opioids and other substance use disorders in primary care. the digits trial is a partnership between kaiser permanente washington health research institute (kpwhri) in seattle, and kaiser permanente washington, a healthcare delivery system in washington state. in this study, the fda-authorized reset and reset-o digital therapeutics will be implemented in kaiser permanente washington primary care clinics. the study will evaluate the extent to which two implementation strategy interventions, health coaching and practice coaching, improve the implementation. primary care clinics are randomized to receive these implementation strategy interventions. each clinic will have a 12-month active implementation period beginning on its date of randomization. to study the continued use of reset and reset-o after the active implementation period is completed, a sustainment period of up 12 months will follow the active implementation period.

specific aims of the digits trial are to: 1. estimate the effect of practice facilitation and health coaching implementation strategies in increasing the reach and fidelity of a digital therapeutic for substance use disorders in primary care clinics. 2. compare the population-level cost-effectiveness of each implementation strategy in increasing reach, fidelity, and abstinence.

Eligibility criteria:
patient inclusion criteria: * had a primary care visit in a participating clinic during the active implementation period or sustainment period * screened positive for substance use on the day of the visit or in the prior year * adult aged 18 years or older at time of visit clinic inclusion criteria: - at least 1 clinician trained in the use of reset/reset-o patient exclusion criteria: - patients who have requested through their health system to opt out of research clinic exclusion criteria: - previously participated in a pilot implementation of reset/reset-o

Keywords: substance use disorders mhealth digital therapeutics primary care implementation science randomized controlled trial factorial trial opioid use disorders
biomarkers of aging as predictors of kidney transplant function

Conditions: Delayed Graft Function; Other Complications of Kidney Transplant

Summary: the primary purpose of this study is to measure the correlation between baseline expression of aging biomarkers, senescetest in blood of organ donor and renal graft function. this pilot study will study patients who are undergoing renal transplantation with organs from extended criteria donors, standard criteria donors or donation after cardiac death and compare ability of senescetest to predict renal graft function immediately after the transplant and at 1 year followup.

presently, donated organs are ranked amongst each other based on a formula for kidney donor patient index (kdpi; a variation of donor risk index) 8 which includes donor demographics and clinical history but no molecular markers of kidney function other than serum creatinine. using kdpi assessment, nearly all ecd kidneys fall into the high-risk category. and while ecd kidneys are associated with higher risk of graft failure, studies note a wide variability in ecd organ quality and the associated graft survival (half-life graft survival 4.5-7.9 years), suggesting that current models of assessing organ quality are inadequate. furthermore, prior to even being assigned a kdpi, over 37% of all kidneys and over 50% of ecd kidneys are discarded based on biopsy findings. however, recent studies called into question the reliance on procurement kidney biopsy reports in making acceptance decisions by demonstrating significant overlap in the biopsy findings between discarded and transplanted kidneys. the use of ecd kidneys is becoming more widespread and, according to a recent report, 70% adults \>65yo and 50% adults between 50 and 64 yo are willing to accept an ecd kidney. therefore, new methodology for assessment of graft viability would increase transplantation rates particularly for organs from older or expanded criteria donors, shorten patient's time on wait list (currently 45 months average 50) and improve their outcomes by taking them off dialysis sooner. here, we propose a new approach-using molecular age markers (collectively referred to as senescetest) to predict kidney graft function.

Eligibility criteria:
inclusion criteria: * donor \> 35 years of age exclusion criteria: * recipient is hiv positive

Keywords: delayed graft function slow graft function renal transplant extended criteria donor biomarker of aging kidney transplant
yoga in controlling symptoms and reducing stress in women with ovarian cancer or breast cancer

Conditions: Breast Cancer; Fatigue; Ovarian Cancer; Psychosocial Effects of Cancer and Its Treatment

Summary: rationale: yoga may improve symptoms and quality of life and reduce stress in patients with ovarian cancer or breast cancer and may help them live more comfortably. purpose: this clinical trial is studying how well yoga works in controlling symptoms and reducing stress in women with ovarian cancer or breast cancer.

objectives: * determine the feasibility of implementing a restorative yoga intervention as a complementary supportive therapy for women with ovarian or breast cancer. * measure changes in fatigue, psychosocial distress (anxiety, depression), psychological well-being (positive emotions), and overall quality of life from baseline to completion of the study treatment. outline: this is a pilot study. patients undergo a 75-minute restorative yoga session once a week for 10 weeks. patients complete questionnaires regarding fatigue, psychological distress (anxiety, depression), positive affect, and quality of life at baseline, immediately after the final yoga session, and then at 2 months after the final yoga session.

Eligibility criteria:
disease characteristics: * diagnosis of breast or ovarian cancer * must be 2-24 months post-primary treatment (e.g., surgery) for breast cancer and/or have had a recurrence of breast cancer within the past 24 months * must be 3-24 months post-primary treatment (e.g., surgery) for ovarian cancer and/or have had a recurrence of ovarian cancer within the past 24 months * hormone receptor status not specified patient characteristics: * female * menopausal status not specified * zubrod performance status 0-3 * no medical contraindications * understands written and spoken english prior concurrent therapy: * see disease characteristics

Keywords: fatigue psychosocial effects of cancer and its treatment recurrent breast cancer stage i breast cancer stage ii breast cancer stage iiia breast cancer stage iiib breast cancer stage iiic breast cancer stage iv breast cancer recurrent ovarian epithelial cancer recurrent ovarian germ cell tumor stage i ovarian epithelial cancer stage i ovarian germ cell tumor stage ii ovarian epithelial cancer stage ii ovarian germ cell tumor stage iii ovarian epithelial cancer stage iii ovarian germ cell tumor stage iv ovarian epithelial cancer stage iv ovarian germ cell tumor
the role of synovitis in osteoarthritis

Conditions: Synovitis of Knee; Osteoarthritis, Knee

Summary: to determine whether platelet-rich-plasma (prp) or ha (hyaluronic acid)injection into synovitis in osteoarthritis(oa) knee can achieve improvement in knee function and reduce synovitis.

methods: sixty patients with oa knee having unilateral or bilateral synovitis validated by ultrasound (n=40) were studied. all the patients were randomized to receive prp (n=40) or hyaluronic acid(ha)(n=40) injection twice at 2-week intervals; clinical assessments were performed using a visual analog scale(vas) and the western ontario and mcmaster universities osteoarthritis index (womac index) before injection at baseline, 4 weeks(first evaluation) and 12 weeks(secondary evaluation). imaging evaluation based on color doppler ultrasound(cdus) and the depth of synovial fluid accumulation ,and the width of synovial hypertrophy was performed simultaneously.

Eligibility criteria:
inclusion criteria: * diagnosed with oa knee according to acr guideline 1. stiffness less than 30min 2. cracking sound during activity 3. more than 30min pain for last 2 months 4. non-bed ridden patients 5. no structure abnormality 6. synovitis was proved by us exclusion criteria: 1. oa knee secondary to other disease 2 . more than 10 years after diagnosing oa 3. under knee surgery within 3 months 4. autoimmune disease 5. refuses inform/consent process
eeg results of deep tms in patients with ocd

Conditions: Obsessive-Compulsive Disorder; EEG With Periodic Abnormalities

Summary: obsessive compulsive disorder (ocd) is a psychiatric disorder in which involuntary thoughts and irresistible behaviors are seen and its prevalence affects 2%-3% of the general population. deep tms is a treatment method that provides stimulation of lower parts of the brain and larger brain volume, and in addition to drug treatment and psychotherapy approaches, magnetic stimulation of localized brain regions and disease symptoms are addressed. the presence of the medial prefrontal cortex and anterior cingulate cortex in the dysfunction on the specified cycle seen in ocd patients indicates that the stimulation of these regions is necessary for a meaningful result in the treatment of deep tms; studies show that the effect of the deep tms method emerges as a result of the stimulation of these regions. 30 patients with ocd will included into the study and dividen into 3 groups (dtms (n=10), dtms + paroxetine (n=10), control(n=10)). patients will evaluated in terms of depression, quality of life, and eeg before and after the intervention.


Eligibility criteria:
inclusion criteria: * being diagnosed with obsessive compulsive disorder within the framework of dsm-5 criteria exclusion criteria: * not volunteering to comply with the research program * presence of a metal piece on the head * having a pacemaker inserted * having had a previous epileptic seizure

Keywords: obsessive compulsive disorder deep transcranial magnetic stimulation mood quality of life eeg
compare the efficacy and safety of rosuvastatin/ezetimibe combination therapy versus rosuvastatin monotherapy in korean patients with left ventricular diastolic dysfunction and hyperlipidemia

Conditions: Left Ventricular Diastolic Dysfunction; Hyperlipidemias

Summary: preserved left ventricular ejection fraction (lvef ≥ 50%) and are accompanied by dyslipidemia (ldl ≥ 100 mg / dl) will be enrolled. only patients who do not meet the exclusion criteria should be enrolled in the study. once the patient is selected, the patient is informed of the study and receives the consent form. patients who are eligible for all of the criteria and who do not qualify as exclusion criteria should be enrolled in the study and randomly assigned in a 1: 1 dose of rosuvastatin/ezetimibe 10/10mg once daily or rosuvastatin 20 mg once daily. patients who previously used statins have a wash-out period of 4 weeks or more. patients will visit outpatient clinic at 12 weeks and 24 weeks after initiation of treatment. physical examination, blood test, and 6 minute working test will be performed. for fasting blood tests, patients visit on an empty stomach. drug adverse events and changes in vital signs or body weight will be checked. after 48 weeks of treatment, the patients will visit outpatient clinic for efficacy evaluation; physical examination, blood test, transthoracic echocardiography, cardiopulmonary exercise test, central blood pressure, and pulse wave velocity. drug adverse events and medication compliance will be checked. the primary endpoint is change of low-density lipoprotein cholesterol and secondary endpoint is improvement of diastolic dysfunction, vac index, peak vo2, distance of 6 minute working test, and clinical outcomes including death, readmission rate.


Eligibility criteria:
inclusion criteria: 1. participants who have left ventricular diastolic dysfunction (relaxation abnormality, pseudonormalization, restrictive pattern) with preserved left ventricular systolic function (left ventricular ejection fraction ≥ 50%) 2. adult participants (≥ 20 years old) who have dyslipidemia and need treatment 3. patients who understand the information about the trial and voluntarily agree to participate in the trial exclusion criteria: 1. baseline fasting low-density lipoprotein cholesterol ≤ 70 mg/dl 2. baseline fasting triglyceride ≥ 400 mg/dl 3. baseline fasting total cholesterol ≥ 300 mg/dl 4. participants who have structural heart disease 5. participants who have prior acute coronary syndrome or cerebrovascular attack within 3 months. 6. renal dysfunction (estimated glomerular filtration rate \< 30ml/min/1.73m2) 7. creatinine phosphokinase elevations greater than three times the upper limit of normal 8. aspartate or alanine aminotransferase elevations greater than three times the upper limit of normal 9. previous history of rhabdomyolysis 10. females who are pregnant or breastfeeding or have a plan for pregnancy 11. life expectancy less than a year.
hcv ras testing in public health programs

Conditions: Hepatitis C; Public Health; Direct Acting Antiviral Agents; Resistance Associated Substitutions

Summary: successful treatment of hepatitis c has been reported to be associated with 62-84% reduction in all-cause mortality (deaths), 68-79% reduction in risk of hcc and 90% reduction in risk of liver transplantation. the efficacy of ns5a inhibitors for the treatment of patients chronically infected with hepatitis c virus (hcv) can be affected by the presence of ns5a resistance-associated substitutions (rass). pre-existence of resistance associated substitutions (rass) to direct antiviral agents (daas) reduces sustained virologic response (svr) rates by 3-53% in hepatitis c virus (hcv) genotype 3 infected patients depending on different predictors and the daa regimen used. this study will prospectively analyze data from the mukhmantri punjab hepatitis c relief fund (mmphcrf) to determine the posttreatment prevalence of various ns5a rass, and their effect on outcomes of treatment with daclatasvir-sofosbuvir or sofosbuvir-ledipasvirin patients with chronic hcv. the study aims to assess the prevalence and effect of rass on sustained virological response (svr) rates in patients with treatment failure to a regimen containing sofosbuvir and ledipasvir/daclatasvir.


Eligibility criteria:
inclusion criteria: * all viremic chronic hepatitis c exclusion criteria: * people with disseminated malignancy, advanced cardiovascular, 18 pulmonary, or neurological disease with short life expectancy were not enrolled

Keywords: resistance associated substitutions hcv
a two arm, multi-site clinical evaluation of the aries hsv 1&2 assay in symptomatic patients

Conditions: Herpes

Summary: the aries hsv 1\&2 assay is a pcr based test for the direct detection and typing of herpes simplex virus (hsv 1 \& 2) dna. the objective is to establish the diagnostic accuracy of aries hsv-1\&2 assay.

the aries hsv 1\&2 assay is a polymerase chain reaction (pcr) based qualitative in vitro diagnostic test for the direct detection and typing of herpes simplex virus (hsv 1 \& 2) dna in male external and internal anogenital, female external and internal anogenital (vaginal), oral and skin lesion specimens. the objective is to establish the diagnostic accuracy of aries hsv-1\&2 assay through a multi-site, method comparison on prospectively collected, left-over de-identified, clinical specimens (i.e. all-comers accrued at enrolled clinical sites between pre-determined dates) as an aid in the diagnosis of herpes infection.

Eligibility criteria:
inclusion criteria: the specimen is from one of the following lesion sources: male internal and external anogenital, female internal anogenital, female external anogenital, oral or skin the specimen is collected and maintained in unexpired copan universal transport medium exclusion criteria: the specimen was not properly collected, transported or stored according to instructions provided by sponsor

Keywords: aries hsv 1&2